Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial

S Kanes, H Colquhoun, H Gunduz-Bruce, S Raines… - The Lancet, 2017 - thelancet.com
Background Post-partum depression is a serious mood disorder in women that might be
triggered by peripartum fluctuations in reproductive hormones. This phase 2 study investigated …

[PDF][PDF] Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma

…, KT Montone, X Xu, S Hotz, S Raines… - Journal of Clinical …, 2005 - researchgate.net
Purpose Tumor cell proliferation is a central feature of melanoma progression. In this study,
we characterized three biomarkers of proliferation (Ki67 expression, dermal mitotic rate [MR], …

Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression

…, H Colquhoun, J Doherty, S Raines… - Human …, 2017 - Wiley Online Library
Objective Preclinical evidence indicates that rapid changes in levels of allopregnanolone,
the predominant metabolite of progesterone, confer dramatic behavioral changes and may …

Brexanolone as adjunctive therapy in super‐refractory status epilepticus

…, AM Husain, H Vaitkevicius, S Raines… - Annals of …, 2017 - Wiley Online Library
Objective Super‐refractory status epilepticus (SRSE) is a life‐threatening form of status
epilepticus that continues or recurs despite 24 hours or more of anesthetic treatment. We …

AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study

…, MA Smith, JJ Doherty, A Cross, S Raines… - Schizophrenia …, 2016 - Elsevier
Introduction Activation of metabotropic glutamate (mGluR2/3) receptors has been proposed
as an alternative mechanism to dopaminergic-based antipsychotics to correct glutamatergic …

Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study

RMA Hirschfeld, RH Weisler, SR Raines… - Journal of clinical …, 2006 - psychiatrist.com
Objective: Quetiapine monotherapy shows efficacy in bipolar depression. The analyses in
this multicenter, double-blind, randomized, fixed-dose, placebocontrolled study evaluated …

Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study

…, M Banov, D Adson, C Datto, S Raines… - Journal of affective …, 2011 - Elsevier
BACKGROUND: Evaluate the efficacy and tolerability of extended release quetiapine
fumarate (quetiapine XR) once-daily monotherapy for patients with major depressive disorder (…

A double‐blind, placebo‐controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence

…, M Kotz, JR Calabrese, S Raines - Alcoholism: Clinical …, 2010 - Wiley Online Library
Background: This study evaluated the efficacy of quetiapine versus placebo as an adjunct to
lithium or divalproex in reducing alcohol consumption in patients with bipolar I disorder and …

[HTML][HTML] Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome

…, C Anderson, I Zafir-Lavie, S Raines… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Severe coronavirus disease 2019 (COVID-19) is associated with a
dysregulated immune response, which can result in cytokine-release syndrome and acute …

[HTML][HTML] SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

E Hoffmann, GG Nomikos, I Kaul, S Raines… - Clinical …, 2020 - Springer
Background SAGE-217, a novel γ-aminobutyric acid A (GABA A ) receptor positive allosteric
modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending …